Brought to you by 
Regeneron and bluebird bio enter cell therapy pact
10 Aug 2018
Executive Summary
Regeneron Pharmaceuticals Inc. and bluebird bio Inc. will lean on each other’s platform discoveries to together discover and develop antibodies and T-cell receptors directed against tumor-specific proteins and peptides.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com